An open-label trial of XXXX for functional @entity662 .

@entity662 @entity1 @entity2544 @entity859 @entity56 @entity158
Visceral @entity56 may play a role in the pathogenesis of functional @entity662 , although the underlying mechanism(s) is unknown. We investigated the effects of @entity2544 , an @entity859 receptor antagonist, on sensory perception and biomechanical properties of esophagus in @entity1 with functional @entity662 . Esophageal balloon distention was performed using impedance planimetry in 21 consecutive @entity1 with functional @entity662 . @entity1 found to have a hypersensitive esophagus received intravenous @entity2544 and balloon distension was repeated. If the @entity56 improved, oral @entity2544 was prescribed for three months as an open label trial. Balloon distension reproduced typical @entity662 in 16 (76%) @entity1 at thresholds suggestive of @entity56 . After @entity2544 infusion, @entity158 thresholds increased in 12 (75%) @entity1 . Median threshold pressures for discomfort and @entity158 improved (P < 0.01). Cross-sectional area increased (P < 0.05) and the tension/strain association shifted to the right (P < 0.01). Seven of eight @entity1 reported sustained improvement in @entity158 after oral @entity2544 . @entity2544 may ameliorate @entity662 in @entity1 with hypersensitive esophagus, possibly by altering @entity859 -mediated nociception.
